A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 4, 2000, Pages 931-937

  Choy, Hak ^a   Devore III, Russell F ^a   Hande, Kenneth R ^a   Porter, Lester L ^b   Rosenblatt, Paul ^b   Yunus, Furhan ^c   Schlabach, Larry ^d   Smith, Clyde ^e   Shyr, Yu ^a   Johnson, David H ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b SAINT THOMAS HOSPITAL   (United States)

^c Methodist Hospitals of Memphis   (United States)

^d ERLANGER HEALTH SYSTEM   (United States)

^e Jackson Madison County General Hospital   (United States)

Author keywords

Carboplatin; Paclitaxel; Thoracic Radiation Therapy

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT FAILURE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE;

EID: 0034237791     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00420-X     Document Type: Article

References (45)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics 1999. A Cancer J. for Clinicians. 49:1999;8-31.
2. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer. 75:(Suppl. 1):1995;191-202.
3. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial . J Natl Cancer Inst. 88:1996;1210-1215.
4. Schaake-Koning C., VaN Den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
5. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (EGOG) 4588 Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
6. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med. 323:1990;940-945.
7. Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials . Br Med J. 1995;899-909.
8. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non-small cell lung cancer. Cancer. 76:1995;593-601.
9. Pignon J.P., Stewart L.A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non-small cell lung cancer Meta analysis . Cancer. 77:1996;2413-2414.
10. Pritchard R.S., Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Ann Intern Med. 125:1996;723-729.
11. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature. 277:1979;665-667.
12. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin. J Cell Biol. 91:1981;479-487.
13. Manfredi J.J., Parness J., Horwitz S.B.L. Taxol binds to cellular microtubules. J Cell Biol. 94:1982;688-696.
14. Choy H., Rodriguez F., Koester S., et al. Investigation of Taxol as a potential radiation sensitizer. Cancer. 71:1993;3774-3778.
15. Geard C.R., Jones J.M., Schiff P.B. Taxol and radiation. J Natl Cancer Inst. 15:1993;89-94.
16. Tishler R., Schiff P.B., Geard C., et al. Taxol A novel radiation sensitizer . Int J Radiat Oncol Biol Phys. 22:1992;613-617.
17. Libmann J., Cook J., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
18. Minarik L., Hall E. Taxol in combination with acute and low dose rate irradiation. Radiat Oncol. 32:1994;124-128.
19. Geard C., Jones J. Radiation and Taxol on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys. 29:1994;565-569.
20. Milas L., Hunter N., Kurdoglu B., et al. Apoptotic death of mitotically arrested cells in murine tumors treated with Taxol. Proc Am Assoc Cancer Res. 35:1994;314.
21. Milas L., Hunter N., Mason K., et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54:1994;3506-3510.
22. Thames H.D. Jr, Peters L.J., Withers H.R., et al. Accelerated fractionated versus hyperfractionation Rationales for several treatments per day . Int J Radiat Oncol Biol Phys. 9:1983;127-138.
23. Cox J.D., Azarnia N., Byhardt R.W., et al. Altered fractionation for non-small cell carcinoma of the lung. Chest. 96:1989;68s-69s.
24. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage Prospective evaluation of a simple formula based on renal function . J Clin Oncol. 7:1989;1748-1756.
25. Crockroft D.W., Gault M.H. Prediction of creatinine clearance from serum cratinine. Nephron. 16:1976;31-41.
26. Arriagada R., Le Chevalier T., Quoix E., et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma A randomized study of 343 patients. ASTRO plenary . In J Radiat Oncol Biol Phys. 20:1991;1183-1190.
27. Perez C.A. Non small cell carcinoma of the lung Dose-time parameters . Cancer Treat Symp. 2:1985;131-142.
28. Liebmann J., Cook J., Fisher J., et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
29. Minarik L., Hall E. Taxol in combination with acute and low dose rate irradiaton. Radiotherapy and Oncology. 32:1994;124-128.
30. Geard C., Jones J. Radiation and taxol on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys. 29:1994;565-569.
31. Choy H., Rodriguez F.F., Koester S., et al. Investigation of Taxol as a potential radiation sensitizer. Cancer. 71:1993;3774-3778.
32. Choy H., Akerley W., Safran H., et al. Phase I trial of out patient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol. 12:1994;2682-2686.
33. Choy H., Safran H., Akerley W., et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 4:1998;1931-1936.
34. Langer C.J., Leighton J.C., Comis R.L., et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer A phase II toxicity, response, and survival analysis . J Clin Oncol. 13:1995;1860-1870.
35. Johnson D.H., Paul D.M., Hande K.R., et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer A phase II trial. J Clin Oncol. 14:1996;2054-2060.
36. Belani CP, Aisner J, Hiponia D; et al. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995;22:(supp 9)7-12.
37. Choy H., Akerley W., Safran H., et al. Multi-Institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced NSCLC. J Clin Oncol. 16:(10):1998;3316-3322.
38. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy Possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11 . J Clin Onc. 8:1990;1543-1555.
39. Shaw E.G., McGinnis W.L., Jett J.R., et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus conomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst. 85:1993;321-323.
40. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol. 13:1995;452-458.
41. McGinnis W.L., Shaw E.G., Jung S.H., et al. Results of a phase III prospective randomized trial comparing standard thoracic radiation therapy (TRT) to twice daily (BID) TRT +/- concomitant etoposide-cisplatin (EP chemotherapy in patients with unresctable stage IIIA/B non-small cell lung cancer (NSCLC). (Abstr.). Proc Am Soc Clin Oncol. 14:1995;355.
42. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carbopolatin/etoposide for stage III non-small cell lung cancer A randomized study . J Clin Oncol. 14:1996;1065-1070.
43. Byhardt R.W., Scott C.B., Ettinger D.S., et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer results of Radiation Therapy Oncology Group 9015. Cancer. 75:1995;2337-2344.
44. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation therapy oncology group protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
45. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 92-04 . Int J Radiat Oncol Biol Phys. 38:1997;149-155.